← Leaderboards
Rebecca Powell
Icahn School Of Medicine At Mount Sinai
$3,892,293
Attributed
$3,892,293
Total exposure
4
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.3M · FY2018–25$2M$1.5M$1M$500K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,892,293 · 4
By mechanism
R01$2,884,867 · 2
R21$1,007,426 · 2
Top collaborators
No co-investigators on record.
Most similar at Icahn School Of Medicine At Mount Sinai
Same institution · by research overlap
- Lynda Coughlan$2,843,986
- Viviana A Simon$21,556,427
- Ana Fernandez-Sesma$24,867,465
- Allen Zheng$179,804
- Lawrence C Kleinman$11,124,863
Others in their field
Other Emerging Leaders on “Mediating”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Yunda Huang · Fred Hutchinson Cancer Center$73,602,469
- James Dale Berry · Brigham And Women'S Hospital$25,538,716
- Ionut Bebu · George Washington University$18,816,779
- Barbara Halina Braffett · George Washington University$18,816,779
- Gary Fanger · Rise Therapeutics, Llc$17,847,765
Research focus
MediatingLactationHuman MilkAntibodiesMilkInfantBreast FeedingCellsMothersPreventInfectionVirus DiseasesSecretory Immunoglobulin AResponseSamplingAntibody ResponseImmunoglobulin GImmune ResponsePhagocytosisBreastfed InfantLactation PeriodCountryIngestionImmunoglobulins
Grant awards (8)
In-depth characterization of myeloid cells in human milk from HIV- and HIV+ donors as potential vehicles of and defenders against vertical transmission of HIV: essential data for targeted therapeutics$850,491
R01 · FY2025 · AI · contact PI
Verification of pigs as an appropriate model for the development of human vaccines targeting the entero-mammary pathway to elicit a robust secretory IgA response in human milk$477,406
R21 · FY2025 · AI · contact PI
Comprehensive assessment of SARS-CoV-2-reactive antibodies in human milk to determine their potential as a COVID-19 therapeutic and as a means to prevent infection of breastfed babies$572,897
R01 · FY2022 · AI · contact PI
Comprehensive assessment of SARS-CoV-2-reactive antibodies in human milk to determine their potential as a COVID-19 therapeutic and as a means to prevent infection of breastfed babies$668,126
R01 · FY2021 · AI · contact PI
Antibody-dependent cellular phagocytosis by human breastmilk leukocytes: impact of antibody class, stage of lactation, and target size$63,895
R21 · FY2021 · HD · contact PI
Comprehensive assessment of SARS-CoV-2-reactive antibodies in human milk to determine their potential as a COVID-19 therapeutic and as a means to prevent infection of breastfed babies$793,353
R01 · FY2020 · AI · contact PI
Antibody-dependent cellular phagocytosis by human breastmilk leukocytes: impact of antibody class, stage of lactation, and target size$211,875
R21 · FY2019 · HD · contact PI
Antibody-dependent cellular phagocytosis by human breastmilk leukocytes: impact of antibody class, stage of lactation, and target size$254,250
R21 · FY2018 · HD · contact PI